Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz.
about
Drug-Drug Interactions with the NS3/4A Protease Inhibitor SimeprevirPharmGKB summary: Efavirenz pathway, pharmacokineticsMethadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and MetabolismAn Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS PatientsCYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African WomenDevelopmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic VariationBuilding Capability for Clinical Pharmacology Research in Sub-Saharan Africa.Sex-Divergent Clinical Outcomes and Precision Medicine: An Important New Role for Institutional Review Boards and Research Ethics Committees.A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications.Role of Cytochrome P450 2B6 Pharmacogenomics in Determining Efavirenz-Mediated Central Nervous System Toxicity, Treatment Outcomes, and Dosage Adjustments in Patients with Human Immunodeficiency Virus Infection.Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.Priming the body to receive the therapeutic agent to redefine treatment benefit/risk profile.HIV and mental illness in Malawi and the neuropsychiatric sequelae of efavirenz.
P2860
Q28084266-576733C3-992F-4CF1-B01E-616B93BB3AFEQ35706069-B3FAC966-EE5D-4CD8-9BE0-2DDC76CFA2A0Q36342286-93F345AD-21FC-4D9B-8B55-2653B4E64D47Q36437792-451A77A3-6542-4C05-A0AD-201C00F5B702Q36966640-8AE0C54A-4213-40A9-8797-DC6DD13F5703Q37062614-3A937AD5-5E50-4102-8B56-2C26CBFAE92EQ38371653-646CCF62-31CD-4698-B767-7E8582E6630BQ38635940-5E7B4721-9EF9-4F3E-BC6B-C84CD5D7A056Q38743628-FEC6F2A6-30EE-4DE7-8827-4EB69FD4B129Q38990321-F86C3A1A-2FDD-4897-B98E-19BFAC2F6C5EQ40050910-37D6855C-6FEB-4351-A6CF-7173635ED291Q46600089-5BAA37D1-BCFA-4C64-91D3-0761BE429818Q55020915-6C861318-75E0-4F01-A330-8FD89054C6B2Q55344050-8A102DD6-E8F3-49A0-A576-48A41B0842A1
P2860
Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Impact of CYP polymorphisms, e ...... tegies: the case of efavirenz.
@en
type
label
Impact of CYP polymorphisms, e ...... tegies: the case of efavirenz.
@en
prefLabel
Impact of CYP polymorphisms, e ...... tegies: the case of efavirenz.
@en
P2093
P2860
P1476
Impact of CYP polymorphisms, e ...... tegies: the case of efavirenz.
@en
P2093
Manoranjenni Chetty
Panjasaram Naidoo
Vasudevan V Chetty
P2860
P2888
P304
P356
10.1007/S00228-013-1634-1
P577
2014-01-05T00:00:00Z
P6179
1026997456